News headlines about Lannett Co (NYSE:LCI) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lannett Co earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.4907775079002 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern’s scoring:
- Lannett Co Inc (LCI) Expected to Post Earnings of $0.52 Per Share (americanbankingnews.com)
- Lannett Co Inc Expected to Earn Q1 2018 Earnings of $0.52 Per Share (LCI) (americanbankingnews.com)
- Financial Contrast: Lannett Co (LCI) and Its Competitors (americanbankingnews.com)
- Consensus Buy Analysis: Lannett Company, Inc. (LCI) – Street Observer (press release) (streetobserver.com)
- ETFs with exposure to Lannett Co., Inc. : October 9, 2017 (finance.yahoo.com)
Several analysts have recently commented on the company. Zacks Investment Research upgraded Lannett Co from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Tuesday, July 18th. Deutsche Bank AG reiterated a “hold” rating and set a $23.00 price target (up previously from $22.00) on shares of Lannett Co in a research note on Monday, July 17th. BidaskClub downgraded Lannett Co from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. ValuEngine upgraded Lannett Co from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Lannett Co in a research note on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $21.80.
Lannett Co (NYSE:LCI) opened at 21.10 on Thursday. The firm’s 50-day moving average price is $18.16 and its 200-day moving average price is $20.19. Lannett Co has a 1-year low of $14.90 and a 1-year high of $27.90. The firm’s market cap is $786.69 million.
Lannett Co (NYSE:LCI) last posted its quarterly earnings results on Wednesday, August 23rd. The company reported $0.40 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.40. Lannett Co had a negative net margin of 0.09% and a positive return on equity of 19.80%. The firm had revenue of $139.10 million for the quarter, compared to analysts’ expectations of $139.01 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The business’s revenue for the quarter was down 17.6% on a year-over-year basis. Equities research analysts anticipate that Lannett Co will post $2.60 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/10/12/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-lannett-co-lci-share-price.html.
Lannett Co Company Profile
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.